Abstract: The present invention relates to new adenoviral coat protein based delivery vehicles. They are based on a modified penton base protomers that assemble into VLPs. Exposed areas of the penton base proteins can be modified to allow the VLP to specifically bind to any target and/or to comprise any desired peptide epitope. Additional cargo, for example drugs, proteins, or nucleic acids, can reversibly or irreversibly attached to the VLP via engineered fibre protein fragments.

Abstract: The present invention relates to new adenoviral coat protein based delivery vehicles. They are based on a modified penton base protomers that assemble into VLPs. Exposed areas of the penton base proteins can be modified to allow the VLP to specifically bind to any target and/or to comprise any desired peptide epitope. Additional cargo, e.g. drugs, proteins, or nucleic acids, can reversibly or irreversibly attached to the VLP via engineered fibre protein fragments.

Abstract: An engineered adenovirus penton base protomer, wherein the penton base protomer comprises a first RGD-loop, a second RGD-loop, a variable loop (V loop), an Adenovirus fiber protein binding cleft, and an N-terminal domain; wherein at least one of the first RGD-loop, the second RGD-loop, and the V loop comprises at least one inserted non-adenoviral antigenic polypeptide; and wherein the engineered adenovirus penton base protomer is capable of assembling into virus-like particles (VLPs).

Abstract: The present invention relates to new adenoviral coat protein based delivery vehicles. They are based on a modified penton base protomers that assemble into VLPs. Exposed areas of the penton base proteins can be modified to allow the VLP to specifically bind to any target and/or to comprise any desired peptide epitope. Additional cargo, e.g. drugs, proteins, or nucleic acids, can reversibly or irreversibly attached to the VLP via engineered fibre protein fragments.

Abstract: The invention concerns transfecting peptide vector, a composition containing said vector and their applications for treating and preventing diseases in human beings and animals. Said vector for transfecting a chemical substance selected in the group consisting of nucleic acid sequences, proteins, peptides and pharmacologically active substances, contains besides said chemical substance, at least a transfecting peptide derived entirely or partially from an adenovirus fibre and comprising at least a zone consisting of at least 50% hydrophobic amino acids selected in the group consisting of alanine, valine, phenylamine, isoleucine, leucine, proline and methionine.

Abstract: A native or recombinant adenoviral protein complex, a pharmaceutical composition containing said protein complex, and the uses thereof for treating and preventing human and animal diseases, are disclosed. Said adenoviral protein complex consists of either 12 pentons each including at least one fiber and a penton base, but no other element from an adenovirus genome, said fiber(s) and said penton base being derived from one or more adenoviruses, said pentons being bound by the penton bases and forming a proteolytic enzyme-stable dodecahedral structure, said complex having a molecular weight between 4.8.times.10.sup.6 and 6.6.times.10.sup.6, and such complexes being known as dodecahedron-penton complexes; or 12 penton bases but no other element from an adenovirus genome, said penton bases being derived from one or more adenoviruses and forming a proteolytic enzyme-stable dodecahedral structure, said complex having a molecular weight between 3.2.times.10.sup.6 and 4.times.10.sup.